ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer A Blinded Study

Wang, Ting; Pan, Wenjun; Zheng, Hang; Zheng, Hongping; Wang, Zhejun; Li, Jia J.; Deng, Chuxia; Yan, Jun*南方医科大学; 上海交通大学; 中山大学; 1; 5
Diseases of the Colon and Rectum2021-7DOI: 10.1097/DCR.0000000000001971
31被引16阅读
引用收藏
分享

摘要

BACKGROUND: Patient-derived tumor organoid culture has emerged as a preclinical model that has the potential to predict individual drug response. However, the predictive accuracy of patient-derived tumor organoid culture models for responses to chemotherapy regimens in stage IV colorectal cancer remains unknown. @@@ OBJECTIVE: The purpose of this study was to evaluate the predictive accuracy of the patient-derived tumor organoid culture model for responses to chemotherapy regimens in stage IV colorectal cancer. @@@ DESIGN: A pilot study was performed to define the half-maximal inhibitory concentration of the response to chemotherapy regimens in the patient-derived tumor organoid culture model. Then, a blinded study was performed to evaluate the predictive accuracy of the patient-derived tumor organoid culture model for responses to chemotherapy regimens. @@@ SETTINGS: Cancer samples were collected from patients with stage IV colorectal cancer at Nanfang Hospital of Southern Medical University in China. @@@ PATIENTS: In the pilot study, 30 patients were enrolled, and 43 samples were collected. In the blinded study, 71 patients were enrolled, and 96 samples were collected. @@@ INTERVENTION: Patient-derived tumor organoid culture and chemotherapy regimens were tested. @@@ MAIN OUTCOME MEASURES: The predictive accuracy of the patient-derived tumor organoid model for responses to chemotherapy regimens was measured. @@@ RESULTS: The median (range) time of organoid culture and drug testing was 9 days (range, 7-14 d). In the pilot study, 30 samples (69.77% [30/43]) were successfully cultured. The half-maximal inhibitory concentration of the chemotherapy response was 10 mu mol/L according to clinical chemotherapy outcomes. In the blinded study, 77 samples (80.21% [77/96]) from 57 patients were successfully cultured. The sensitivity, specificity, and accuracy of the patient-derived tumor organoid model for predicting responses to chemotherapy regimens were 63.33%, 94.12%, and 79.69%. @@@ LIMITATIONS: This was a blinded study rather than a prospective randomized controlled study. @@@ CONCLUSIONS: The patient-derived tumor organoid culture model effectively predicts responses to existing chemotherapy regimens for individual patients.

学科与关键词

关键词
AccuracyChemotherapy responseColorectal cancerPatient-derived tumor organoidPredictive model
相关
加载中…
  • Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients With Stage IV Colorectal Cancer After Surgery
    Wang, Ting; Tang, Yuting; Pan, Wenjun; Yan, Botao; Hao, Yifan; Zeng, Yunli; Chen, Zexin; Lan, Jianqiang; Zhao, Shuhan; Deng, Chuxia; Zheng, Hang*; Yan, Jun*Diseases of the Colon and Rectum, 2023, 66(5): 733-743.被引 2
  • Application of tumoroids derived from advanced colorectal cancer patients to predict individual response to chemotherapy
    Yao, Lei; Zao, Xiao-Long; Pan, Xiao-Fei; Zhang, Hao-Gang; Wang, Fu-Jing; Qiao, Peng-Fei*JOURNAL OF CHEMOTHERAPY, 2023, 35(2): 104-116.被引 4
  • Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study
    Wang, Han-Min; Zhang, Chan-Yuan; Peng, Kai-Cheng; Chen, Ze-Xin; Su, Jun-Wei; Li, Yu-Fa; Li, Wen-Feng; Gao, Qing-Yun; Zhang, Shi-Ling; Chen, Yu-Qing; Zhou, Qing; Xu, Cong; Xu, Chong-Rui; Wang, Zhen; Su, Jian; Yan, Hong-Hong; Zhang, Xu-Chao; Chen, Hua-Jun*; Wu, Yi-Long*; Yang, Jin-Ji*CELL REPORTS MEDICINE, 2023, 4(2): 100911.被引 18
查看全部 →

发表信息

论文状态
公开发表
期刊
Diseases of the Colon and Rectum
发表日期
2021-07
卷期
第 64 卷, 第 7 期
页码
833-850
DOI
10.1097/DCR.0000000000001971
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81773117, 81572530]; Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Cancer [2020B121201004]; Special Fund for Guangdong Province Public Research and Capacity Building [2014B020215002]; Natural Science Foundation of Guangdong Province [2015A030308006]; Guangzhou Industry University Research Cooperative Innovation Major Project [201704020062]; Wu Jieping Medical Foundation [320.2710.1851]; Clinical Research Project of Southern Medical University [LC2016PY010]; President Fund of Nanfang Hospital [2019Z023]; High-Level Research Matching Foundation of Nanfang Hospital [2014067]; Scientific Research Foundation for HighLevel Talents in Nanfang Hospital of Southern Medical University [201404280056]; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation [pdjhb0100, pdjh2017a0093]; Training Program for Undergraduate Innovation and Entrepreneurship [201912121008, 202012121091]; Scientific Enlightenment Plan of Southern Medical University [B1000494]

作者

  • W

    Wang, Ting (第一作者)

    1 · southern med univ

  • P

    Pan, Wenjun

    1 · southern med univ

查看全部 8 位作者收起作者
  • Z

    Zheng, Hang

    1 · southern med univ

  • Z

    Zheng, Hongping

    5 · sun yat sen univ

  • W

    Wang, Zhejun

  • L

    Li, Jia J.

    shanghai jiao tong univ

  • D

    Deng, Chuxia

  • Y

    Yan, Jun (通讯)

    1 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417